Niraparib in Combination With Pembrolizumab in Patients With Triple-negative Breast Cancer or Ovarian Cancer
Status:
Completed
Trial end date:
2021-09-17
Target enrollment:
Participant gender:
Summary
This Phase 1/2 study will evaluate the safety and efficacy of combination treatment with
niraparib and pembrolizumab (MK-3475) in patients with advanced or metastatic triple-negative
breast cancer or recurrent ovarian cancer. (KEYNOTE-162)